why choose us

300×250 Ad Slot

Research Article: Pan-immune-inflammation value predicts 2-year recurrence after chemoradiotherapy in nasopharyngeal carcinoma

Date Published: 2026-06-24

Abstract:
Nasopharyngeal carcinoma (NPC) remains a clinically challenging head and neck malignancy with a substantial risk of post-treatment recurrence, underscoring the need for accessible biomarkers that complement established staging and Epstein-Barr virus (EBV)-DNA assessment. This retrospective cohort study evaluated the prognostic utility of the pan-immune-inflammation value (PIV), a composite biomarker integrating neutrophil, platelet, monocyte, and lymphocyte counts, for predicting 2-year recurrence in patients with NPC treated with chemoradiotherapy. We retrospectively analyzed 306 patients with NPC treated at a tertiary center between February 2017 and April 2023, with follow-up until recurrence or April 2025. Baseline clinical, laboratory, imaging, and pretreatment EBV-DNA data were evaluated, and patients were stratified into recurrence and recurrence-free groups according to 2-year follow-up. Predictive performance and survival associations were assessed using receiver operating characteristic (ROC) analysis, Kaplan-Meier analysis with the log-rank test, and univariate and multivariate Cox regression models. PIV was significantly elevated in the recurrence group (380.88 ± 204.99 vs. 329.76 ± 193.92, P = 0.037), indicating its association with immune-inflammatory activation. Receiver operating characteristic (ROC) analysis demonstrated moderate predictive accuracy (AUC = 0.582, 95% CI: 0.512–0.651, P = 0.023), with an optimal cutoff of 381.55 yielding 44.7% sensitivity and 73.1% specificity. Kaplan-Meier survival analysis revealed shorter recurrence-free survival (RFS) in high-PIV patients (mean RFS: 18.69 ± 0.75 vs. 20.41 ± 0.48 months, log-rank P = 0.004). Univariate and multivariate Cox regression confirmed advanced T stage (HR = 2.354, 95% CI: 1.421–3.900, P = 0.001) and elevated PIV (HR = 1.698, 95% CI: 1.130–2.553, P = 0.011) as independent predictors of recurrence. These findings suggest that PIV may serve as a cost-effective adjunctive tool for recurrence risk stratification, although the retrospective design and moderate sensitivity indicate that prospective multicenter validation is required before routine clinical application.

Introduction:
Nasopharyngeal carcinoma (NPC) remains a clinically challenging head and neck malignancy with a substantial risk of post-treatment recurrence, underscoring the need for accessible biomarkers that complement established staging and Epstein-Barr virus (EBV)-DNA assessment. This retrospective cohort study evaluated the prognostic utility of the pan-immune-inflammation value (PIV), a composite biomarker integrating neutrophil, platelet, monocyte, and lymphocyte counts, for predicting 2-year recurrence in patients with…

Read more

300×250 Ad Slot